Nature Outlook |

Bladder cancer

Nature Outlook: Bladder cancer

For three decades, the treatment of bladder cancer stood still. There were no new drugs and no improvements in diagnosis or survival rates. But all of that has changed, and now people with the disease and researchers have more options and hope. This Outlook discusses topics such as: how checkpoint-inhibitor drugs are helping those affected to survive for longer; why a healthy bladder is not sterile; and how the genetics of bladder cancer is revealing some surprising connections.

This Nature Outlook is editorially independent. It is produced with third party financial support. About this content.

Content

  • Nature | Outlook

    The diagnostics, treatment and five-year survival rates for bladder cancer are largely unchanged since the 1990s. Research into cancer genomics, risk factors and immune therapies could hold the key to progress against this malignant disease.

    • Chris Berdik
  • Nature | Outlook

    People with metastatic bladder cancer once faced meagre treatment options and a grim prognosis. But immunotherapy has started to yield results.

    • Michael Eisenstein
  • Nature | Outlook

    Bladder cancer is more deadly in women than in men. That needs to change, say James McKiernan and Denise Asafu-Adjei.

    • James McKiernan
    •  &  Denise Asafu-Adjei
  • Nature | Outlook

    Once thought to be sterile, the bladder contains microbes that could influence the development and treatment of cancer.

    • Claire Ainsworth
  • Nature | Outlook

    What happens when a professor of theatre finds out she has bladder cancer? She writes a one-woman play about it, of course.

    • Tammy Worth